个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Jiao, Xiao-Dong[1] ; Qin, Bao-Dong[1] ; Wang, Zhan[1] ; Liu, Ke[1] ; Wu, Ying[1] ; Ling, Yan[1] ; Qin, Wen-Xing[1] ; Wang, Miao-Miao[1] ; Yuan, Ling-Yan[1] ; Barreto, Savio George[2] ; Kim, Anthony W.[3] ; Mak, Kimberley[4] ; Li, Hao[5] ; Xu, Yuan-Yuan[6] ; Qiu, Xiao-Ming[7] ; Wu, Min[8] ; Jin, Min[9] ; Xu, Li-Chao[10] ; Zhong, Yi[11] ; Yang, Hui[12] ; Chen, Xue-Qin[13] ; Zeng, Yu[14] ; Shi, Jun[15] ; Zhu, Wen-Yu[16] ; Ding, Qing-Qing[17] ; Jia, Wei[18] ; Liu, Su-Fen[19] ; Zhou, Jun-Jing[20] ; Shen, Hong[21] ; Yao, Shi-Hua[22] ; Guo, Zhao-Ji[23] ; Li, Ting[24] ; Zhou, Pei-Juan[25] ; Dong, Xue-Wei[13,26] ; Lu, Wen-Feng[16,27] ; Coleman, Robert L.[28] ; Akce, Mehmet[29] ; Akladios, Cherif[30] ; Puccetti, Francesco[31] ; Zang, Yuan-Sheng[1] ;
机构： [1]Naval Med Univ, Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China [2]Flinders Med Ctr, Dept Surg, Bedford Pk, SA, Australia [3]Keck Sch Med Univ Southern Calif, Div Thorac Surg, Los Angeles, CA USA [4]Boston Univ, Sch Med, Boston Med Ctr, Dept Radiat Oncol, Boston, MA USA [5]Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Dept Med Oncol, Shanghai, Peoples R China [6]Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Surg Oncol, Shanghai, Peoples R China [7]Sichuan Univ, West China Hosp, Lung Canc Ctr, Chengdu, Peoples R China [8]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gynecol & Obstet, Wuhan, Peoples R China [9]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China [10]Fudan Univ, Shanghai Canc Ctr, Dept Intervent Radiol, Shanghai, Peoples R China [11]Shanghai Univ Tradit Chinese Med, Shanghai Tradit Chinese Med Integrated Hosp, Dept Med Oncol, Shanghai, Peoples R China [12]Nanjing Med Univ, Suzhou Municipal Hosp, Dept Med Oncol, Suzhou, Peoples R China [13]Zhejiang Univ Sch Med, Hangzhou Peoples Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China [14]Shanghai Tongji Univ, Shanghai Tongji Hosp, Dept Pathol, Shanghai, Peoples R China [15]Nanjing Med Univ, Changzhou Peoples Hosp No 2, Dept Gastrointestinal Surg, Changzhou, Peoples R China [16]Nanjing Med Univ, Changzhou Peoples Hosp No 2, Dept Med Oncol, Changzhou, Peoples R China [17]Nanjing Med Univ, Jiangsu Prov Peoples Hosp, Dept Geriatr Oncol, Nanjing, Peoples R China [18]Shanghai Univ Tradit Chinese Med, Shanghai Tradit Chinese Med Integrated Hosp, Dept Resp, Shanghai, Peoples R China [19]Nanjing Med Univ, Changzhou Peoples Hosp No 2, Dept Gynecol, Changzhou, Peoples R China [20]Jiangnan Univ, Wuxi Peoples Hosp No 4, Dept Hepatobiliary & Pancreat Surg, Wuxi, Peoples R China [21]Zhejiang Univ, Sch Med, Dept Med Oncol, Affiliated Hosp 2, Hangzhou, Peoples R China [22]Naval Med Univ, Changhai Hosp, Dept Thorac Surg, Shanghai, Peoples R China [23]Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou, Peoples R China [24]Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China [25]Shanghai Jiao Tong Univ, Shanghai Renji Hosp, Dept Tradit Chinese Med, Shanghai, Peoples R China [26]Soochow Univ, Peoples Hosp Changzhou 1, Dept Gastrointestinal Surg, Changzhou, Peoples R China [27]Fudan Univ, Zhongshan Hosp, Dept Integrat Med, Shanghai, Peoples R China [28]Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX USA [29]Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA USA [30]Univ Strasbourg, Dept Obstet & Gynecol, Strasbourg, France [31]San Raffaele Hosp IRCCS, Dept Gastrointestinal Surg, Milan, Italy
出处：
DOI： 10.3389/fonc.2023.860711
ISSN：

关键词： intractable cancer basket trial targeted therapy gene alteration precision medicine

摘要：
PurposeWe evaluated he effects of molecular guided-targeted therapy for intractable cancer. Also, the epidemiology of druggable gene alterations in Chinese population was investigated. Materials and methodsThe Long March Pathway (ClinicalTrials.gov identifier: NCT03239015) is a non-randomized, open-label, phase II trial consisting of several basket studies examining the molecular profiles of intractable cancers in the Chinese population. The trial aimed to 1) evaluate the efficacy of targeted therapy for intractable cancer and 2) identify the molecular epidemiology of the tier II gene alterations among Chinese pan-cancer patients. ResultsIn the first stage, molecular profiles of 520 intractable pan-cancer patients were identified, and 115 patients were identified to have tier II gene alterations. Then, 27 of these 115 patients received targeted therapy based on molecular profiles. The overall response rate (ORR) was 29.6% (8/27), and the disease control rate (DCR) was 44.4% (12/27). The median duration of response (DOR) was 4.80 months (95% CI, 3.33-27.2), and median progression-free survival (PFS) was 4.67 months (95% CI, 2.33-9.50). In the second stage, molecular epidemiology of 17,841 Chinese pan-cancer patients demonstrated that the frequency of tier II gene alterations across cancer types is 17.7%. Bladder cancer had the most tier-II alterations (26.1%), followed by breast cancer (22.4%), and non-small cell lung cancer (NSCLC; 20.2%). ConclusionThe Long March Pathway trial demonstrated a significant clinical benefit for intractable cancer from molecular-guided targeted therapy in the Chinese population. The frequency of tier II gene alterations across cancer types supports the feasibility of molecular-guided targeted therapy under basket trials.

基金：
AME Cancer Collaborative Group
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Naval Med Univ, Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jiao Xiao-Dong,Qin Bao-Dong,Wang Zhan,et al.Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)[J].FRONTIERS IN ONCOLOGY.2023,13:doi:10.3389/fonc.2023.860711.
APA：
Jiao, Xiao-Dong,Qin, Bao-Dong,Wang, Zhan,Liu, Ke,Wu, Ying...&Zang, Yuan-Sheng.(2023).Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway).FRONTIERS IN ONCOLOGY,13,
MLA：
Jiao, Xiao-Dong,et al."Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway)".FRONTIERS IN ONCOLOGY 13.(2023)

相关文献

[1]Expert consensus on the diagnosis and treatment of NTRK gene fusion solid tumors in China [2]Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China [3]Radiomics: A radiological evidence-based artificial intelligence technique to facilitate personalized precision medicine in hepatocellular carcinoma [4]Triboelectric nanogenerator and artificial intelligence to promote precision medicine for cancer [5]Study Progress of Radiomics With Machine Learning for Precision Medicine in Bladder Cancer Management. [6]Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. [7]Expert Consensus on the Diagnosis and Treatment of NRG1/2 Gene Fusion Solid Tumors [8]Integrative Comparison of mRNA Expression Patterns in Breast Cancers from Caucasian and Asian Americans with Implications for Precision Medicine [9]A radiomics model of predicting tumor volume change of patients with stage III non-small cell lung cancer after radiotherapy [10]First-line treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) in China in the era of precision medicine

资源点击量：43378 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号